Q-omics provides the consensus-scored ADAMTS19 profile across patient tissues and cancer cell-line models. ADAMTS19 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, ADAMTS19 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, ADAMTS19 RNA expression shows 14,580 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UCEC, KIRC, and THYM as cancer lineages where ADAMTS19 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ADAMTS19 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ADAMTS19 survival associations across molecular data types. ADAMTS19 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ADAMTS19 RNA expression–survival associations across cancer types. High ADAMTS19 expression shows unfavorable associations in UVM and LUSC, but favorable associations in UCEC, LGG, PAAD and ESCA. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify UCEC as the clearest survival context for ADAMTS19 RNA expression.
This table summarizes ADAMTS19 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ADAMTS19. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ADAMTS19 shows lower tumor expression in KIRC, KIRP, HNSC, KICH and BLCA and higher tumor expression in BRCA. The KIRC box plot shows higher ADAMTS19 RNA expression in normal versus tumor tissue (log2 FC = −0.803, t-test p < 0.001).
This table shows molecular features associated with ADAMTS19 in patient tissues and cancer cell lines. In patient samples, ADAMTS19 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ADAMTS19 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in LIVER and LARGE_INTESTINE.
